PDC*line Pharma Announces the Administration of a First Patient With Its Therapeutic Cancer Vaccine Candidate (PDC*lung01) Targeting Non-small Cell Lung Cancer
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under the supervision of Dr. Anne Sibille, principal investigator for the Liege University Hospital (Belgium).
The objectives of the phase I/II trial (PDC-LUNG-101) are to assess t...